ETON Stock: Insider Activity, Filings & Research

Eton Pharmaceuticals, Inc. (ETON) — Drillr’s hub for ETON insider activity, SEC filings, earnings signals and AI research. Over the trailing 3 months, ETON insiders filed 0 open-market buys and 7 sales (SEC Form 4).

Sentiment

0/100

Buys (3m)

Sells (3m)

Net (3m)

-$7.1M

Insider trades by month Buys Sells

Sep

Oct

Jun

Aug

May

Context3-month price +57.5%Institutions mixed (13F)

Date	Insider	Type	Shares	Price
May 29, 2026	BRYNJELSEN SEANdirector, officer: President & CEO	Sell	148	$32.67
May 29, 2026	BRYNJELSEN SEANdirector, officer: President & CEO	Sell	119,852	$31.88
May 27, 2026	Krempa Davidofficer: Chief Business Officer	Option	25,000	$1.38
May 27, 2026	Krempa Davidofficer: Chief Business Officer	Option	12,524	$1.37
May 27, 2026	Krempa Davidofficer: Chief Business Officer	Sell	37,524	$31.49
May 27, 2026	Krempa Davidofficer: Chief Business Officer	Option	30,591	$3.58
May 27, 2026	Krempa Davidofficer: Chief Business Officer	Sell	9,315	$33.88
May 27, 2026	Krempa Davidofficer: Chief Business Officer	Option	12,476	$1.37
May 27, 2026	Krempa Davidofficer: Chief Business Officer	Option	7,203	$3.58
May 27, 2026	Krempa Davidofficer: Chief Business Officer	Sell	19,679	$31.47
May 27, 2026	Krempa Davidofficer: Chief Business Officer	Sell	32,963	$33.22
May 27, 2026	Krempa Davidofficer: Chief Business Officer	Sell	519	$35.00
Apr 22, 2026	RIEDEL NORBERT Gdirector	Option	12,500	$7.31
Apr 22, 2026	RIEDEL NORBERT Gdirector	Option	19,655	$8.61
Jan 14, 2026	Krempa Davidofficer: Chief Business Officer	Tax	1,942	$15.62

Source: ETON SEC Form 4 filings, latest May 29, 2026. For informational purposes only — not investment advice.

Overview

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a specialty pharmaceutical company founded in 2017 and based in Deer Park, Illinois. The company went public in November 2018 and focuses on developing and commercializing pharmaceutical products for rare diseases, particularly those affecting fewer than 10,000 patients in the United States. Since its inception, Eton has transformed from a development-stage company into a commercial enterprise with multiple approved products, achieving consistent revenue growth and reaching near-profitability by 2024.

Business

Eton Pharmaceuticals operates in the rare disease pharmaceutical sector, a specialized segment of the broader biotechnology and pharmaceutical industry. Rare diseases, also known as orphan diseases, are medical conditions that affect a small percentage of the population - typically fewer than 200,000 people in the United States. The rare disease pharmaceutical market is characterized by high unmet medical needs, limited treatment options, and favorable regulatory pathways that provide incentives for drug development. The company's product portfolio consists of several key therapeutic areas: 1. Pediatric Endocrinology Products (approximately 40-50% of revenue): This segment includes **Alkindi Sprinkle**, a hydrocortisone granule formulation for treating adrenocortical insufficiency in children under 17 years of age. Adrenocortical insufficiency occurs when the adrenal glands don't produce enough cortisol, a critical hormone for life. The company also recently acquired **Increlex**, a growth hormone therapy for children with severe primary insulin-like growth factor-1 deficiency, and is developing **ET-400**, a liquid hydrocortisone formulation for the same patient population as Alkindi Sprinkle. 2. Metabolic Disorder Treatments (approximately 30-40% of revenue): This includes **Carglumic Acid** for treating hyperammonemia (excess ammonia in blood) due to a rare genetic enzyme deficiency, **PKU GOLIKE** for phenylketonuria (a genetic disorder affecting protein metabolism), and **Galzin** for Wilson disease (a genetic disorder causing copper accumulation in organs). 3. Hospital and Critical Care Products (approximately 10-20% of revenue): These include **Biorphen** (phenylephrine injection) and **Rezipres** for treating low blood pressure during anesthesia, and **Alaway Preservative Free** for allergic conjunctivitis. The company also maintains a robust development pipeline with products like **ET-600** for diabetes insipidus (a condition causing excessive urination), **ET-700** (extended-release zinc for Wilson disease), and **Amglidia** for neonatal diabetes mellitus.

Revenue model

Eton Pharmaceuticals generates revenue primarily through direct product sales to specialty pharmacies, hospitals, and healthcare providers, along with some licensing revenue. The company's business model is built on three strategic pillars: organic growth of existing commercial products, advancement of internal pipeline development, and value-creating acquisitions of commercial or late-stage rare disease assets. The company's customers are primarily specialty pharmacies that serve rare disease patients, pediatric hospitals and clinics, and healthcare providers specializing in rare diseases. Eton has built a dedicated sales force of approximately 12-17 rare disease specialists who focus on key prescribing physicians in pediatric endocrinology, metabolic disorders, and hospital settings. Several factors influence Eton's profit margins and revenue potential. Positive margin drivers include the company's focus on rare diseases with limited competition, which allows for premium pricing; the transition from third-party manufacturing to internal production capabilities; economies of scale as patient numbers grow; and patent protection extending to 2043 for key products like ET-400. The company targets adjusted gross margins exceeding 75% by 2028. Margin pressures could arise from increased competition as patents expire, regulatory challenges that could delay product launches, manufacturing cost inflation, and the need for continued investment in sales force expansion and clinical trials. The company's heavy reliance on a small number of products also creates concentration risk, though this is being addressed through active business development efforts. Additionally, the rare disease market's small patient populations mean that revenue growth depends heavily on successful patient identification and physician education initiatives.

Competitive moat

Eton Pharmaceuticals possesses a moderate but growing competitive moat built primarily around regulatory barriers, specialized market knowledge, and patient switching costs inherent in rare disease treatments. The company's strongest defensive position lies in its **regulatory expertise and FDA relationships** - developing treatments for rare diseases requires navigating complex orphan drug pathways, and Eton has demonstrated consistent success in obtaining approvals and maintaining compliance. The company benefits from high patient switching costs in rare disease treatments, where physicians are reluctant to change therapies for patients with life-threatening conditions once a treatment is working effectively. This creates natural patient retention, as evidenced by Alkindi Sprinkle's 17 consecutive quarters of growth. Additionally, Eton has built **specialized sales relationships** with the limited number of physicians who treat these rare conditions, creating barriers for new entrants who would need to establish similar trust and expertise. However, Eton's moat has notable limitations. The company operates in a highly regulated industry where patent expirations, generic competition, and regulatory changes can quickly erode competitive advantages. Most of Eton's current products are reformulations or improved versions of existing molecules rather than novel drug discoveries, which limits the depth of intellectual property protection. **Competition from larger pharmaceutical companies** represents a significant threat, as major players like Pfizer, Novartis, and other specialty pharma companies have substantially greater resources for research, development, and market access. The company's moat is strengthened by its **acquisition strategy and pipeline development**, which aims to build a portfolio of 10+ rare disease products, creating operational synergies and reducing dependence on any single therapy. However, this strategy requires continued capital allocation success and faces competition from well-funded acquirers in the rare disease space.

Risks & safety

Eton Pharmaceuticals presents a **moderate margin of safety** with improving but still developing financial fundamentals. **Cash and Liquidity Position:** - Cash and short-term investments: $17.4 million as of Q1 2025 - Current ratio: 1.97, indicating adequate short-term liquidity - Positive operating cash flow: $2.1 million in Q1 2025, showing operational improvement - Free cash flow turned positive: $2.1 million in Q1 2025 vs. negative $8.9 million in Q4 2024 **Debt and Solvency:** - Very low debt-to-equity ratio: 0.004, indicating minimal financial leverage - Total debt burden is minimal relative to assets - No significant solvency concerns in the near term given cash position and improving operations **Valuation Metrics:** - Price-to-book ratio: 14.3, indicating premium valuation - Enterprise value to EBITDA: Not meaningful due to minimal EBITDA - Revenue multiple appears reasonable given 117% year-over-year growth and rare disease focus - Company targeting $80 million revenue run rate by end of 2025 **Other Considerations:** - Achieved near-profitability with positive EBITDA trends - Strong revenue growth trajectory (117% year-over-year in Q1 2025) - Pipeline products provide potential upside but also execution risk - Dependence on small number of products creates concentration risk

Recent development

Over the past few years, Eton Pharmaceuticals has executed a significant strategic transformation from a development-stage company to a commercial rare disease specialist. The company's most notable strategic pivot has been its **aggressive acquisition strategy**, exemplified by the 2024 acquisitions of **Increlex** from Ipsen and **Galzin** for Wilson disease treatment. These acquisitions immediately expanded Eton's patient base and revenue potential, with Increlex growing from 67 to over 90 active patients within months of acquisition. The company has also made substantial **operational improvements**, including building an internal sales force of rare disease specialists and transitioning from third-party manufacturing to more direct control over production. This vertical integration strategy has enabled better gross margins and more reliable supply chain management. **Pipeline advancement** has been another key development focus. The company successfully submitted the NDA for **ET-400**, a liquid hydrocortisone formulation, which received FDA approval in 2025 and represents a potential $50 million revenue opportunity when combined with Alkindi Sprinkle. Similarly, **ET-600** for diabetes insipidus has progressed through clinical trials with NDA submission completed, targeting a potential Q1 2026 approval. The company has also demonstrated **strategic portfolio management** by focusing exclusively on rare diseases affecting fewer than 10,000 patients, allowing for specialized expertise and reduced competition. Recent product launches include the successful relaunch of Galzin with a zero co-pay patient assistance program and the introduction of PKU GOLIKE, targeting the $100 million phenylketonuria medical foods market. **Commercial execution improvements** have been evident in consistent quarterly growth, with Alkindi Sprinkle achieving 17 consecutive quarters of revenue increases and the company reaching positive GAAP net income ahead of schedule in 2024.

ETON company profile · for informational purposes only — not investment advice.

Track ETON with Drillr

SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.

Try Drillr for free